24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer

F Cardoso,A Bardia,F André,D.W Cescon,H Mcarthur,M Telli,S Loi,J Cortes,P Schmid,N Harbeck,C Denkert,C Jackisch,L Jia,K Hirshfield,V Karantza

doi:10.1093/annonc/mdz416.023

24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer

F Cardoso, A Bardia + Show 13 more

Open Access

https://doi.org/10.1093/annonc/mdz416.023

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 1, 2019
Citations: 1	License type: publisher-specific-oa

Affiliation: Champalimaud Foundation, Massachusetts General Hospital, Institut Gustave Roussy, Princess Margaret Cancer Centre, Cedars-Sinai Medical Center, Stanford University, Peter MacCallum Cancer Centre, Queen Mary University of London, Ludwig-Maximilians-Universität München, Universitätsklinikum Gießen und Marburg, Sana Klinikum Offenbach, MSD (United States)

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

More From: Annals of Oncology

Paper Title

Journal

Date

Author

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.